White Papers
The pricing and market access (P&MA) landscape in China has been rapidly evolving as the country continuously attempts to balance rewarding innovation and sustainability of healthcare funding. China represents a unique and dynamic market archetype for manufacturers especially in terms of P&MA strategies.
China’s aging population (≥60 years) is estimated to exceed 400 million by 2035 driving a significant rise in government healthcare expenditure and medical insurance subsidies in the future. As such, the Chinese government has acknowledged the important…
Read Now
White Papers
Share estimates from demand studies in primary market research (PMR) are a critical input for any forecast—their accuracy is paramount for successful brand planning.
Successful prediction is often elusive—from 2020 through 2022, only one in ten products had actual performance that aligned with forecasted expectations.*
Recognizing this challenge, Trinity experts developed a method that significantly improves prediction of future prescribing behavior in demand studies.
The Challenge
It is often difficult for Healthcare Professionals (HCPs) to offer precise share estimates when…
Read Now
White Papers
Trinity Life Sciences has been tracking and analyzing the challenges of commercialization and new product launches in the Biopharma industry for years (see our 2022 white paper, Empowering the Next-Generation Launch Model). One method we have leveraged to track the challenges in commercialization is new product launch performance, comparing first calendar year actual sales with consensus Wall Street analyst forecast estimates at time of launch for novel product (New Molecular Entities) launches within the U.S.
In this white paper, we…
Read Now
White Papers
In the pharmaceutical industry, there has been ongoing discussion whether the Commercial Operations departments should become a globalized function. Over the past decade as companies have become more global in commercializing their products, organizations have been investigating the effectiveness of the Commercial Operations ecosystem.
For 20 years, TGaS Advisors, a Division of Trinity Life Sciences, has been working with U.S. Commercial Operations leaders in the pharmaceutical industry, providing benchmarks and insights across 9 capability areas/departments and over 50 unique functions.…
Read Now
White Papers
Navigating the MarTech Jungle: An Analysis of The Technology Powering 160+ Pharma Brands.
In today’s hyperconnected digital landscape, the marketing technology (MarTech) space has exploded into a complex ecosystem of over 10,000 potential vendors and services. The sheer volume of available options presents opportunities for pharmaceutical brands to optimize their performance and gain a competitive advantage.
In this white paper, TGaS has meticulously reviewed the technology powering 160+ patient websites to understand which tools are leading in their respective categories…
Read Now
White Papers
This report, the fifth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2019, scoring each on its commercial performance, therapeutic value, and R&D investment. 2019 saw 53 unique drug and biologic approvals, of which the majority were neurology (~23%) followed by oncology (~21%). In this…
Read Now
White Papers
Pharmaceutical companies that are seeking ways to engage and partner with integrated delivery networks must understand this: IDNs are evolving in ways that have a profound effect on how healthcare is managed, what care paths are followed and which populations are carved out for special attention.
TGaS Advisors, a division of Trinity Life Sciences, conducted 15 in-depth interviews with key decision-makers from advanced healthcare systems in the U.S. to understand their perspectives on what is driving IDNs and what they…
Read Now
White Papers
Gene therapies’ single administration nature presents a unique commercial challenge for biopharmaceutical companies; unlike traditional small molecule or biologic therapies that can be dosed chronically or repeatedly on an “as needed” basis, the one-time per patient administration of a gene therapy means that as time passes, the eligible population decreases in size.
In this white paper, Trinity Life Sciences’ cell and gene therapy experts explore the unique opportunities that life sciences executives can utilize to unlock eligible patient populations and…
Read Now
White Papers
Trinity Life Sciences’ Evidence, Value, Access and Pricing experts identify the key global market access trends that will enable life sciences executives to identify opportunities, combat challenges and ultimately secure success in 2023.
Download this white paper to understand:
The five key market access trends emanating from 2022 that foretell the opportunities and challenges that lie ahead in 2023 (and beyond).
In-depth insights from 11 U.S. and 24 ex-U.S. payers from Trinity Life Sciences’ ‘Global Market Access Payer Survey’.
How…
Read Now
White Papers
As the market becomes increasingly crowded and budget constraints continue in China, downward pricing pressure to secure National Reimbursement Drug List (NRDL) inclusion remains the top challenge for multinational pharma companies in this market. However, the significant uptake post-NRDL inclusion and broad access offer substantial opportunities for innovative products with clinical differentiation.
In this white paper, Trinity Life Sciences explores the highlights of the 2021 NRDL negotiation; including trends within the oncology, rare disease and chronic disease therapeutic areas…
Read Now
